Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation

Journal of Nuclear Medicine

Volumn 46, Issue 5, 2005, Pages 840-849

  Dewaraja, Yuni K ^a   Wilderman, Scott J ^a   Ljungberg, Michael ^b   Koral, Kenneth F ^a   Zasadny, Kenneth ^c   Kaminiski, Mark S ^d  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b LUND UNIVERSITY   (Sweden)

^c PFIZER INC   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

3 dimensional dosimetry; 131I; Monte Carlo dosimetry; Radioimmunotherapy; SPECT

Indexed keywords

IODINE 131; RADIOISOTOPE; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

ARTICLE; ATTENUATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOSE CALCULATION; DOSIMETRY; DRUG ABSORPTION; HISTOGRAM; HUMAN; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION SCATTERING; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ABDOMINAL TUMOR; ALGORITHM; BODY BURDEN; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED RADIOTHERAPY; IMAGE QUALITY; INSTRUMENTATION; METHODOLOGY; RADIATION DOSE; RADIOMETRY; RELATIVE BIOLOGIC EFFECTIVENESS; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING;

ABDOMINAL NEOPLASMS; ALGORITHMS; BODY BURDEN; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; IODINE RADIOISOTOPES; PHANTOMS, IMAGING; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, COMPUTER-ASSISTED; RELATIVE BIOLOGICAL EFFECTIVENESS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 20644463730     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Press O, Early J, Appelbaum F, et al. Phase II trial of I-131 B1 (anti CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet 1995;346:336-340.
2. Kaminshi MS, Zasadny KR, Francis IR, et al. Iodine-131 anti B1 radioimmunotherapy for B-cel lymphoma. J Clin Oncol. 1996;14:1974-1981.
3. DeNardo GL, Lambom KR, Goldstein DS, Kroger LA, DeNardo SJ. Increased survival associated with radiolabeled lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Cancer. 1997;80:2706-2711.
4. Kaminski MS, Tuck M, Estes J, et al. I-131 tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449.
5. Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem cell support for the treatment of neuroblastoma. J Clin Oncol. 2002; 20:2142-2149.
6. Matthay KK, Huberty JP, Harmer RS, et al. Efficacy and safely of I-131 metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. J Nucl Biol Med. 1991;35:244-247.
7. DeNardo GL, DeNardo SJ, Shen S, et al. Factors affecting 131-I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non Hodgkin's lymphoma and chronic lymphocytic leukemia. J Nucl Med. 1999;40:1317-1326.
8. 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med. 2003;44:260-268.
9. 131I-tositumomab therapy of previously untreated lymphoma patients. J Nucl Med. 2003;44:457-464.
10. DeNardo GL, DeNardo SJ, Goldstein DS, et al. Maximum tolerated dose, toxicity and efficacy of I-131-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol. 1998;16:3246-3256.
11. Weiden PL, Breitz HB. Pretargeted radioimmunotherapy for the treatment of non-Hodgkin's lymphoma. Clin Rev Oncol Hematol. 2001;40:37-51.
12. Davis TA, Kaminski MS, Leonard JP, et al. Results of a randomized trial of Bexxar (tositumomab and I 131 tositumomab) vs unlabeled tositumomab in patients with relapsed or refractory low grade or transformed non-Hodgkin's lymphoma [abstract]. Blood 2001;98:843.
13. Dewaraja YK, Ljungberg M, Koral KF. Accuracy of I-131 tumor quantification in radioimmunotherapy using SPECT imaging with an ultra high-energy collimator: Monte Carlo study, J Nucl Med. 2000;41:1760-1767.
14. Smith MF, Gilland DR, Coleman RE, Jaszczak RJ. Quantitative imaging of I-131 distributions in brain tumors with pinhole SPECT: a phantom study. J Nucl Med. 1998;39:856-864.
15. Gonzalez Trotter DE, Jaszczak RJ, Bowsher JE, Akabani G, Greer KL. High resolution absolute SPECT quantitation for I-131 distributions used in the treatment of lymphoma: a phantom study. IEEE Trans Nucl Sci. 2001;48:707-714.
16. Ljungberg M, Sjogreen K, Liu X, Frey E, Dewaraja YK, Strand S. A three dimensional absorbed dose calculation method based on quantitative SPECT for radionuclide therapy: evaluation for I-131 using Monte Carlo simulation. J Nucl Med. 2002;43:1101-1109.
17. Koral KF, Yendiki A, Lin Q, Dewaraja YK, Fessler JA. Determining total I-131 activity within a VOI using SPECT, a UHE collimator, OSEM and a constant conversion factor. IEEE Trans Nucl Sci. 2004;51:611-618.
18. Loevinger R, Budinger TF, Watson EE. MIRD Primer. Reston, VA: Society of Nuclear Medicine; 1999:5-6.
19. Johnson TK, Colby SB. Photon contribution to tumor dose from considerations of I-131 radiolabeled antibody uptake in liver, spleen and whole body. Med Phys. 1993;6:1667-1674.
20. Stabin MG. Internal dosimetry in the use of radiopharmaceuticals in therapy science at a crossroads? Cancer Biother Radiopharm. 1999:14:81-89.
21. Zanzonico PB. Internal radionuclide radiation dosimetry: a review of basic concepts and recent developments. J Nucl Med. 2000;41:297-308.
22. Furhang EE, Chui CS, Kolbert KS, et al. Implementation of Monte Carlo dosimetry method for patient-specific internal emitter therapy. Med Phys. 1997; 24:1163-1172.
23. Yoriyaz H, Stabin MG, dos Santos A. Monte Carlo MCNP-4B based absorbed dose distribution estimates for patient-specific dosimetry. J Nucl Med. 2001;42: 662-669.
24. Zubal IG, Harrell CR, Smith EO, Rattner Z, Gindi G, Hoffer PB. Computerized three-dimensional segmented human anatomy. Med Phys. 1994;21:299-302.
25. Ljungberg M, Larsson A, Johansson L. A new collimator simulation in SIMIND based on the Delta scattering technique. Conference Record: IEEE Nuclear Science Symposium and Medical Imaging Conference; October 16-22, 2004, Rome, Italy.
26. Sempau J, Wilderman S, Bielajew AF. DPM, a fast, accurate Monte Carlo code optimized for photon and electron radiotherapy treatment planning dose calculations. Phys Med Biol. 2000;45:2263-2291.
27. Chetty IJ, Moran JM, Nurushev DL, et al. Experimental validation of the DPM Monte Carlo code using minimally scattered election beams in heterogeneous media. Phys Med Biol. 2002;47:1837-1851.
28. Wilderman SJ, Gunnett RB, Kearfott KJ, Dewaraja YK. Fast CT/SPECT derived 3D Monte Carlo dose computations for I-131 internal emtter therapy. Conference Record: IEEE Nuclear Science Symposium and Medical Imaging Conference; October 16-22, 2004; Rome, Italy.
29. Stabin M. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;7:538-546.
30. 131I-anti-B antibody therapy of previously untreated patients with lymphoma. J Nucl Med. 2000;41:1579-1586.
31. 124I PET and 3-dimensional internal dosimetry (3D-ID) software. J Nucl Med. 2004;45:1366-1372.
32. Frey EC, He B, Sgouros G, et al. Comparison of planar, quantitative SPECT, and combined planar-quantitative SPECT organ residence time estimation methods for targeted radionuclide therapy dosimetry [abstract]. J Nucl Med. 2004; 45(suppl):46P.